Novartis has announced that its investigational, once-daily, fixed-dose inhaled QMF149 (indacaterol acetate and mometasone furoate) was superior to mometasone furoate (MF) in improving through forced expiratory volume in one second after 26 weeks.
The superior improvement in lung function occurred in patients with asthma who remain uncontrolled on treatment with inhaled corticosteroid (ICS) at medium or high dose, or long-acting bet agonist at low dose.
